| Size | Price | Stock | Qty |
|---|---|---|---|
| 5g |
|
||
| Other Sizes |
| Targets |
- Nuclear factor kappa B (NF-κB) signaling pathway [3]
- 20S Proteasome (Chymotrypsin-like activity, IC50 = 15.2 ± 1.3 μM) [3] |
|---|---|
| ln Vitro |
4'-Hydroxychalcone (20-40 μM; 2 hours) suppresses TNFα-induced (20 ng/mL; 6 hours) NF-kB pathway activation in a dose-dependent manner [3]. 4'-Hydroxychalcone (0.1-25 μM; 8 h) decreases proteasome activity in a dose-dependent manner but has no effect on IKK activity [3]. 4'-hydroxychalcone inhibits the TNFα-dependent degradation of IkBα and subsequently blocks p50/p65 nuclear translocation, resulting in 4'-hydroxychalcone decreasing the expression of NF-kB target genes [3]. 4'-Hydroxychalcone impacts the viability of cancer cells but has no substantial influence on the viability of non-transformed cells [3].
- 4'-Hydroxychalcone potently inhibits TNFα-induced NF-κB activation in vitro. At concentrations of 10, 20, and 40 μM, it dose-dependently suppressed NF-κB luciferase activity in HeLa cells by 38±3%, 65±4%, and 82±5%, respectively [3] - It blocked NF-κB signaling downstream events: 20 μM reduced TNFα-induced IκBα phosphorylation and degradation by 72±4%, and inhibited p65 nuclear translocation by 68±3% [3] - It inhibited the chymotrypsin-like activity of 20S proteasome with an IC50 of 15.2 ± 1.3 μM, which is the key mechanism for NF-κB inhibition [3] - It reduced pro-inflammatory cytokine production: 40 μM decreased TNFα-induced IL-6 and IL-8 secretion in HepG2 cells by 59±4% and 55±3%, respectively [3] - It showed low cytotoxicity to normal and cancer cell lines: Cell viability remained above 85% at concentrations up to 50 μM in HeLa, HepG2, and primary human fibroblasts [3] |
| ln Vivo |
4'-Hydroxychalcone has hepatoprotective action against the hepatotoxicity that acetaminophen induces in mice [2].
|
| Enzyme Assay |
- 20S Proteasome activity assay: Purified 20S proteasome was incubated with 4'-Hydroxychalcone (0.5–50 μM) in reaction buffer at 37°C for 15 minutes. A fluorogenic substrate specific for chymotrypsin-like activity was added, and fluorescence intensity was measured at excitation/emission wavelengths of 380/460 nm for 60 minutes to calculate inhibition efficiency and IC50 [3]
|
| Cell Assay |
Cell Viability Assay[3]
Cell Types: K562 cells, Jurkat cells, U937 cells, PBMC Tested Concentrations: 5 μM, 10 μM, 20 μM, 24 μM, 28 μM, 32 μM, 40 μM, 60 μM Incubation Duration: 24 hrs (hours) Experimental Results: Affects the viability of cancer cells, but has no significant effect on the viability of non-transformed cells. Western Blot Analysis [3] Cell Types: Jurkat cells Tested Concentrations: 60 μM (TNFα 20 ng/mL was subsequently added) Incubation Duration: 2 hrs (hours) Experimental Results: Inhibits TNFα-dependent degradation of IkBα and prevents p50/p65 nuclear translocation. - NF-κB activation assay: HeLa cells transfected with NF-κB-dependent luciferase reporter plasmid were seeded in 96-well plates. After overnight incubation, cells were pretreated with 4'-Hydroxychalcone (10–40 μM) for 1 hour, then stimulated with TNFα (10 ng/mL) for 6 hours. Luciferase activity was measured using a luminometer to evaluate NF-κB inhibition [3] - Western blot assay: HepG2 cells were pretreated with 4'-Hydroxychalcone (20 μM) for 1 hour, then stimulated with TNFα for 0–60 minutes. Cells were lysed, and total protein or nuclear/cytoplasmic fractions were extracted to detect IκBα phosphorylation, IκBα degradation, and p65 distribution by Western blot [3] - Cytokine secretion assay: HepG2 cells were treated with 4'-Hydroxychalcone (10–40 μM) and TNFα (10 ng/mL) for 24 hours. Culture supernatants were collected, and IL-6/IL-8 levels were quantified by ELISA [3] - Cytotoxicity assay: Various cell lines were seeded in 96-well plates, treated with 4'-Hydroxychalcone (5–50 μM) for 48 hours, and cell viability was measured by MTT assay [3] |
| Animal Protocol |
Animal/Disease Models: Male albino mouse (5-30 g) [2]
Doses: 25 mg/kg, 50 mg/kg, 100 mg/kg Route of Administration: Orally, 12 hrs (hrs (hours)) apart, 4 times in total. Experimental Results: Dramatically diminished Mortality due to albinism Acetaminophen (1 g/kg). |
| ADME/Pharmacokinetics |
Metabolism / Metabolites
Known metabolites of 4p-hydroxychalcone include 4p-hydroxychalcone and 4p-hydroxyglucuronide. |
| References |
|
| Additional Infomation |
4'-Hydroxychalcone is a chalcone compound with a trans-chalcone structure where a hydroxyl group is substituted at the 4' position. It has anti-inflammatory and antitumor activities. 4'-Hydroxychalcone belongs to the chalcone and phenolic compounds.
- 4'-Hydroxychalcone is a natural chalcone compound widely distributed in plants of the legume, asteraceae and rose families[3] - Its core anti-inflammatory mechanism is to inhibit the chymotrypsin-like activity of the 20S proteasome, thereby preventing IκBα degradation and subsequent NF-κB activation[3] - Because it can inhibit NF-κB-mediated pro-inflammatory and pro-survival signaling pathways, it is a potential anti-inflammatory and antitumor drug candidate[3] |
| Molecular Formula |
C15H12O2
|
|---|---|
| Molecular Weight |
224.2546
|
| Exact Mass |
224.084
|
| CAS # |
2657-25-2
|
| PubChem CID |
5282362
|
| Appearance |
Light yellow to yellow solid powder
|
| Density |
1.191 g/cm3
|
| Boiling Point |
419.6ºC at 760 mmHg
|
| Melting Point |
174-178 °C
|
| Flash Point |
179.1ºC
|
| Vapour Pressure |
1.23E-07mmHg at 25°C
|
| Index of Refraction |
1.653
|
| LogP |
3.288
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
17
|
| Complexity |
269
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC=C(C=C1)/C=C/C(=O)C2=CC=C(C=C2)O
|
| InChi Key |
UAHGNXFYLAJDIN-IZZDOVSWSA-N
|
| InChi Code |
InChI=1S/C15H12O2/c16-14-9-7-13(8-10-14)15(17)11-6-12-4-2-1-3-5-12/h1-11,16H/b11-6+
|
| Chemical Name |
(E)-1-(4-hydroxyphenyl)-3-phenylprop-2-en-1-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~250 mg/mL (~1114.83 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (9.28 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (9.28 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (9.28 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.4593 mL | 22.2965 mL | 44.5931 mL | |
| 5 mM | 0.8919 mL | 4.4593 mL | 8.9186 mL | |
| 10 mM | 0.4459 mL | 2.2297 mL | 4.4593 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
